How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,348 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

7321. Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00179582 Recruitment Status : Terminated (Lack of enrollment) First Posted : September 16, 2005 Last Update Posted : February 27, 2019 Sponsor: Beth Israel Deaconess Medical Center (...) Information provided by (Responsible Party): Anthony Lembo, Beth Israel Deaconess Medical Center Study Details Study Description Go to Brief Summary: To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS Condition or disease Intervention/treatment Phase IBS Drug: VSL#3 Not Applicable Detailed Description: The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms. Study Design Go to Layout table

2005 Clinical Trials

7322. A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of diarrhea predominant Irritable Bowel Syndrome Willingness to make daily calls on a touch-tone telephone Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one since your IBS diagnosis and in the past 5 years Willingness to use an approved method of birth control Exclusion Criteria: Serious medical or surgical conditions Gastrointestinal Cancers, Crohns Disease (...) A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of Crofelemer

2005 Clinical Trials

7323. Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants

: Lactobacillus GG containing yogurt Other: Placebo yogurt Yogurt NOT containing the active LGG bacteria Placebo Comparator: Placebo yogurt Regular yogurt, NOT containing LGG Outcome Measures Go to Primary Outcome Measures : Growth, as measured by weight for age and height [ Time Frame: 3 months ] Secondary Outcome Measures : Number of episodes of diarrhea [ Time Frame: 3 months ] duration of episodes of diarrhea [ Time Frame: 3 months ] Eligibility Criteria Go to Information from the National Library (...) Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2005 Clinical Trials

7324. Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

stools/24 hr plus one or more signs or symptoms of enteric infection Secondary Outcome Measures : Occurrence of mild diarrhea (1 or 2 unformed stools/24 hr plus a sign or symptom) Treatment failure (not well in five days) Occurrence of moderate to severe abdominal pain/cramps or intestinal gas related symptoms Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members (...) study completion. An approved birth control patch for at least two cycles before enrollment and continuing during therapy. OR Complete abstinence from intercourse for the two weeks of medication. Exclusion Criteria: Acute diarrhea (criteria for travelers’ diarrhea above) within the past week Diarrhea developing within 24 hours of study enrollment In Mexico for more than 72 hours Receipt of one of the following classes of drugs: fluoroquinolone (any drug in class), macrolide or azalide

2004 Clinical Trials

7325. Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. Secondary Outcome Measures : Number of Episodes of Diarrhea by Patient [ Time Frame: 6 months overall ] Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis. Number (...) Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2007 Clinical Trials

7326. Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

-induced diarrhea (grades 2-4) in patients with anal or rectal cancer. Secondary Compare the quality of life of patients treated with this drug vs placebo. Compare the number of hospitalizations and use of antidiarrheal agents (e.g., Imodium®) related to diarrhea (or its complications) in patients treated with these drugs. Compare treatment delays and/or dose reductions (chemotherapy and radiotherapy) in patients treated with these drugs. OUTLINE: This is a double-blind, placebo-controlled, randomized (...) to Primary Outcome Measures : Prevention of the incidence of moderate, severe, or life-threatening diarrhea Secondary Outcome Measures : Quality of life Economic measures Validity of the Functional Alterations due to Changes in Elimination-Changes in Bowel Function, the Quality of Life-Radiation Therapy Instrument, and the Expand Prostate Index Composite-Bowel questionnaires Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea Eligibility Criteria Go to Information from

2004 Clinical Trials

7327. Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Posted : April 16, 2015 Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy. Condition or disease Intervention/treatment Phase Irritable Colon Irritable Bowel Syndrome (IBS) Drug (...) Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2003 Clinical Trials

7328. Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

Posted : April 16, 2015 Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy. Condition or disease Intervention/treatment Phase Irritable Colon Irritable Bowel Syndrome (IBS (...) Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2003 Clinical Trials

7329. Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children

Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00055107 Recruitment Status : Completed First Posted : February 20, 2003 Last Update Posted : February 16, 2012 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID

2003 Clinical Trials

7330. Impact of Home Zinc Treatment for Acute Diarrhea in Children

for Acute Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00530829 Recruitment Status : Completed First Posted : September 18, 2007 Last Update Posted : March 9, 2010 Sponsor: Centers for Disease Control and Prevention Collaborators: Kenya Medical Research Institute International (...) . The primary outcome will be a comparison of the prevalence of diarrhea in home zinc versus nonhome zinc villages. Secondary outcomes will be the incidence of repeat episodes of diarrhea, the duration of diarrheal illness, the prevalence of acute respiratory infection, and the effect of malaria infection on treatment with zinc. Thirty-three villages (approximately 1300 children) will be enrolled and children will be followed for 1 year. Significance of results. If this study shows zinc given at home

2007 Clinical Trials

7331. PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

after completion of the course of study medication. Secondary Outcome Measures : Recurrence [ Time Frame: Study days 11-40 ] Percentage of subjects with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. Global Cure [ Time Frame: End of Study ] Achieving a cure (...) PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2007 Clinical Trials

7332. Preventing Antibiotic-Associated DiarRhea Using Erceflora

] Secondary Outcome Measures : Reduction in the number of antibiotic-associated diarrhea events per day [ Time Frame: From baseline to end of treatment ] Reduction in the severity of diarrhea events [ Time Frame: From baseline to end of treatment ] Reduction in Gastrointestinal-related symptoms (nausea, vomiting, abdominal pain)over-all reduction in the number of hospitalization days beween control and treatment groups. [ Time Frame: From baseline to end of treatment ] Reduction in C. dificille (...) Investigators Layout table for investigator information Study Director: Paz Figueroa Sanofi More Information Go to Layout table for additonal information Responsible Party: Medical Affairs Study Director, sanofi-aventis ClinicalTrials.gov Identifier: Other Study ID Numbers: ENTER_L_01125 First Posted: March 14, 2007 Last Update Posted: September 5, 2008 Last Verified: September 2008 Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Diarrhea, Infantile Signs and Symptoms, Digestive Signs

2007 Clinical Trials

7333. A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea

Sponsor: Genzyme, a Sanofi Company Information provided by: Sanofi Study Details Study Description Go to Brief Summary: Approximately 24 patients will be entered into this study taking place in Canada. The aim of this study is to determine if an investigational drug is absorbed (taken up) in patients with C. difficile-associated diarrhea (CDAD). The investigational drug will be given in addition to current standard antibiotic treatment so that all patients will receive active medication. All study (...) related care is provided including doctor visits, physical exams, laboratory tests, and study medication. The total length of participation is approximately 7 days. Condition or disease Intervention/treatment Phase Pseudomembranous Colitis Clostridium Difficile Diarrhea Antibiotic-Associated Diarrhea Drug: tolevamer potassium-sodium (GT267-004) Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 24 participants Allocation

2006 Clinical Trials

7334. Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea

Industrialized Country; Capable of giving Informed Consent Exclusion Criteria: Fever (>100.3 degrees); Pregnant or Breast Feeding or Not using adequate birth control; Known or Suspected (co-)Infection with non-bacterial pathogen; Symptoms of Gastroenteritis of >72 hours; Bloody Diarrhea; Concomitant antibacterial with activity against enteric bacterial pathogens; History of IBD; Unable/Unwilling to comply with study protocol; > 2 doses of anti-diarrheal medication within 24 hours; Antimicrobial Treatment (...) Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety

2006 Clinical Trials

7335. Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea

Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Azithromycin (...) , With or Without Loperamide, to Treat Travelers' Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00359970 Recruitment Status : Completed First Posted : August 3, 2006 Last Update Posted : June 19, 2015 Sponsor: The University of Texas Health Science Center, Houston Information provided by (Responsible

2006 Clinical Trials

7336. Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation

, 2011 Sponsor: Swedish Medical Center Collaborator: Hoffmann-La Roche Information provided by: Swedish Medical Center Study Details Study Description Go to Brief Summary: We hypothesize that the administration of a combination of high numbers of probiotic bacteria will maintain normal bowel function and significantly moderate or obviate Immunosuppression Associated Diarrhea following kidney transplantation. Condition or disease Intervention/treatment Phase Immunosuppressant Associated Diarrhea Drug (...) transplantation, utilizing a daily questionnaire, stool cultures and C. Difficile. [ Time Frame: 5 months ] Secondary Outcome Measures : Determine the impact of IAD on therapeutic drug levels. Taper or change of immunosuppressive medications due to IAD. [ Time Frame: 5 months ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study

2006 Clinical Trials

7337. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. (PubMed)

. Eighteen (25%) were subsequently proven to have CDAD; two (3%) had laxative-induced diarrhea; two (3%) had diarrhea secondary to a medication (colchicine [one] and nelfinavir [one]); one (1%) had diarrhea caused by bowel preparation for colonoscopy. The remaining 49 (68%) did not have a clearly established diarrhea etiology. (Four did not undergo stool examination.) Statistical analysis (chi(2) test) demonstrated a significant decrease in symptoms for metronidazole-treated patients with CDAD versus (...) in two community teaching hospitals receiving metronidazole for empiric treatment of presumptive CDAD. A database including antibiotic usage, fever, white blood cell count, feeding formula usage, comorbidity, and response to therapy was maintained.Seventy-one patients on the medical (50), surgical (18), obstetric (two), and trauma (one) service were identified. Sixty-two had nosocomial diarrhea; nine had diarrhea on admission. Seventy (97%) received antibiotics; one (3%) was on nelfinavir only

2003 American Journal of Gastroenterology

7338. Therapy of travelers' diarrhea with rifaximin on various continents. (PubMed)

; exclusion criteria included primarily medication that could influence the outcome. Subjects were treated for 3 days, three times daily; follow-up lasted 5 days. For each 24-h period, the subjects completed a diary card. Pre- and posttreatment stool, blood, and urine samples were assessed.Among the 380 volunteers, median time to the last unformed stool was 32.5 and 32.9 h in both rifaximin groups, compared with 60.0 h with placebo (p = 0.0001). Also, secondary clinical outcome measures were favorably (...) Therapy of travelers' diarrhea with rifaximin on various continents. Our aim was to compare the efficacy and safety of rifaximin, a virtually nonabsorbed antibiotic, 600 and 1200 mg per day, with placebo in patients with travelers' diarrhea.This was a multicenter, 1:1:1 randomized, parallel-group, double-blind study, conducted in Antigua, Guatemala; Guadalajara and Morelia, Mexico; and the coast of Kenya north and south of Mombasa. Adult patients with acute travelers' diarrhea were recruited

2003 The American journal of gastroenterology Controlled trial quality: uncertain

7339. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. (PubMed)

rate of adequate relief of IBS pain and discomfort. Secondary endpoints included 48-wk average satisfactory control rates of urgency, stool frequency, stool consistency, and bloating. Other efficacy endpoints were average monthly adequate relief and urgency control rates and impact of provided rescue medication.Alosetron-treated patients had significantly greater 48-wk average adequate relief (p= 0.01) and urgency control (p < 0.001) rates, regardless of rescue medication use, compared with placebo (...) Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. To assess long-term safety and efficacy of alosetron in women with severe, chronic diarrhea-predominant IBS and in a subset having more frequent urgency (i.e., bowel urgency at least 10 of 14 days during screening).Randomized patients received either alosetron 1 mg (n = 351) or placebo (n = 363) twice daily during a 48-wk, double-blind study. The primary endpoint was the 48-wk average

2004 The American journal of gastroenterology Controlled trial quality: predicted high

7340. Knowledge and use of secondary contraception among patients requesting termination of pregnancy. (Full text)

no medical advice. There was a range of knowledge of postcoital contraceptive methods. Knowledge of how to deal with forgotten pills, severe vomiting, severe diarrhea, and concurrent antibiotic treatment among the 422 patients who had ever used the combined pill also was variable. 19% of the 372 patients treated by general practitioners knew 4 correct answers, but 50% of the 50 patients in community family planning clinics answered correctly 4 times. Differences could not be explained by other (...) Knowledge and use of secondary contraception among patients requesting termination of pregnancy. 8461770 1993 05 05 2008 11 20 0959-8138 306 6877 1993 Feb 27 BMJ (Clinical research ed.) BMJ Knowledge and use of secondary contraception among patients requesting termination of pregnancy. 556-7 Bromham D R DR Fertility Control Unit, St James's University Hospital, Leeds. Cartmill R S RS eng Journal Article England BMJ 8900488 0959-8138 0 Contraceptives, Postcoital AIM IM J BMJ. 1993 Apr 3;306(6882

1993 BMJ : British Medical Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>